Table 5.
HR estimates of progression-free survival between statins and lung cancer
| No. of reports | Pooled HR (95% CI) | I2 (%) | P for heterogeneity | |
|---|---|---|---|---|
| Overall estimation | 6 | 0.93 (0.76–1.13) | 39.90 | 0.14 |
| Subgroup analysis | ||||
| Study design | ||||
| Cohort | 3 | 0.74 (0.47–1.17) | 58.50 | 0.29 |
| RCT | 3 | 0.99 (0.87–1.13) | 0 | 0.37 |
| Cancer type | ||||
| NSCLC | 5 | 0.88 (0.65–1.19) | 50.10 | 0.093 |
| SCLC | 1 | 0.98 (0.85–1.13) | ||
| Combined treatment | ||||
| TKIs | 3 | 0.85 (0.49–1.49) | 70.90 | 0.032 |
| Chemotherapy | 2 | 0.99 (0.86–1.12) | 0.00 | 0.836 |
Abbreviations: NSCLC, non-small-cell lung cancer; RCT, randomized controlled trial; SCLC, small cell lung cancer; TKIs, tyrosine kinase inhibitors.